What's Happening?
Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has been awarded the Immunology Abstract Award at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Conference. The award recognizes the company's scientific abstract
on 'Anti-14-3-3eta Autoantibodies,' a novel diagnostic biomarker that distinguishes axial spondyloarthritis from mechanical back pain. This abstract was selected from approximately 800 submissions and will be featured in an ePoster Discussion at the conference. The research, led by Dr. Anthony Marotta, highlights the potential of the biomarker to address significant diagnostic challenges in inflammatory back pain.
Why It's Important?
The recognition of Augurex's research underscores the potential impact of their diagnostic biomarker in improving the diagnosis and management of axial spondyloarthritis, a condition often misdiagnosed as mechanical back pain. This advancement could lead to more accurate and timely diagnoses, allowing for better-targeted treatments and improved patient outcomes. The award also highlights the importance of continued innovation in diagnostic tools for autoimmune disorders, which can significantly enhance clinical practice and patient care.
What's Next?
Dr. Marotta will formally receive the award at the ADLM IID Division Awards Reception and present the research during an ePoster Discussion. Augurex will also showcase their SPINEstat® diagnostic assay at the ADLM Clinical Lab Expo, where it is a finalist for the Disruptive Technology Award. These events provide opportunities for further engagement with the diagnostics community and potential collaborations to advance the application of the biomarker in clinical settings.
